2025 Update of Cellular Immunotherapy for Plasma Cell Disorders , 2025
A comparison of cryopreserved and noncryopreserved peripheral blood hematopoietic stem cells for autologous transplantation in multiple myeloma: a study from the chronic malignancies working party of the EBMT , 2026
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone , 2026
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study , 2026
[11C]-Methionine PET/CT in evaluation of bone marrow infiltration and usage as a prognostic tool in multiple myeloma , 2026
Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study , 2026
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy , 2026
Somatic variants and frequencies of familial myeloma germline predisposition genes among patients within the CoMMpass dataset , 2025
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant , 2025
Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network , 2025
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials , 2025
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial , 2025
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma , 2025
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma , 2025
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS , 2025
Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT , 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions , 2025
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia , 2025
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT , 2024
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network , 2025
Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial , 2025
Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods , 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma , 2025
Familial Multiple Myeloma: Insights From Epidemiology and Underlying Germline Genetic Predisposition to the Clinic , 2025
Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel , 2025
A plain language summary of the ICARIA study, comparing isatuximab–pomalidomide– dexamethasone with pomalidomide– dexamethasone in people with multiple myeloma , 2025
Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: An indirect comparison using patient-level data. , 2025
Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial. , 2025
Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial. , 2025
DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features. , 2025
Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf). , 2025
Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study. , 2025
Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials. , 2025
Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis. , 2025
Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study , 2025
Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group , 2025
A comparison of Cryopreserved and non-Cryopreserved Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma: A study from the Chronic Malignancies Working Party of the EBMT , 2025
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial , 2025
VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG) , 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial , 2025
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma , 2024
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma , 2024
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT , 2024
Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases , 2024
Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation , 2020
Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG) , 2024
Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study , 2024
Transcriptome analysis of beta-catenin-related genes in CD34+ haematopoietic stem and progenitor cells from patients with AML , 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma , 2024
Current Landscape of iPSC Haplobanks , 2024
A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma , 2024
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). , 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis , 2024
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment , 2024
In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide , 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison , 2024
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma , 2024
Inhibition of O6‐methylguanine‐DNA‐methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT‐proficient cells , 2024
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients , 2024
A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity , 2021
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group , 2023
Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation , 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT , 2023
Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center , 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network , 2023
Werner helicase is required for proliferation and DNA damage repair in multiple myeloma , 2022
Upfront autologous transplantation still improving outcomes in patients with multiple myeloma , 2023
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome , 2023
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study , 2023
HIV‐1 integrase inhibitor raltegravir promotes DNA damage‐induced apoptosis in multiple myeloma , 2023
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT , 2023
A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset , 2023
Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data , 2023
Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT , 2023
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial , 2023
Highlighting the Prognostic Importance of Measurable Residual Disease Amongst Acute Myeloid Leukemia Risk Factors , 2021
A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker , 2016
Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center , 2018
Upfront autologous transplantation still improving outcomes in patients with multiple myeloma , 2022
First Experience of 11C-Methionine PET in Multiple Myeloma in Turkey , 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma , 2022
Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper , 2022
Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful? , 2022
When a Monoclonal Gammopathy Is Not Multiple Myeloma , 2022
Health\u2010related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient\u2010reported outcomes from the APOLLO trial , 2022
Chronic graft-versus-host disease complicated by membranous glomerulonephritis , 1999
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma , 2012
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma , 2022
Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA , 2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial , 2022
Manual Versus Automated Volume Reduction of Cord Blood , 2022
Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT , 2022
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT , 2022
Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis , 2022
The efficacy and safety of second allogeneic hematopoietic stem cell transplantation. , 2022
Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia , 2022
Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies , 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study , 2022
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics , 2022
Health\u2010related quality of life in patients with\n <scp>light chain<\/scp>\n amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone\u2009±\u2009daratumumab: Results from the\n <scp>ANDROMEDA<\/scp>\n study , 2022
Extramedullary disease in multiple myeloma: a systematic literature review , 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019 , 2022
Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease , 2022
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study , 2022
Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells , 2019
Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center , 2018
CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation , 2001
A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma , 2019
PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma , 2019
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome , 2021
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome , 2019
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. , 2020
A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG-PET/CT , 2020
Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience. , 2020
β-catenin mutations in acute myeloid leukemia , 2020
β-catenin mutations in acute myeloid leukemia , 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk , 2020
Efficacy and safety of weekly carfilzomib (70 mg/m sup2/sup ), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies/title , 2020
Efficacy and safety of weekly carfilzomib (70\u2009mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies , 2020
Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values , 2014
Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) , 2020
Insights on Multiple Myeloma Treatment Strategies , 2019
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation , 2015
Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation , 2021
Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications , 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study , 2021
Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study , 2021
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma , 2021
Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT) , 2021
Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT) , 2020
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis , 2021
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network , 2021
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma , 2021
Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group , 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide\u2010pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics , 2021
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network , 2021
Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review , 2021
Health\u2010related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial , 2021
Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party , 2021
Expert review on soft\u2010tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations , 2021
A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT , 2021
Prognostic impact of early\u2010versus\u2010late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT , 2021
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA , 2021
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study , 2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group , 2021
Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma , 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial , 2021
CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma , 2021
Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors , 2021
β-catenin mutations in acute myeloid leukemia , 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk , 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network , 2020
β-catenin mutations in acute myeloid leukemia , 2020
The outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4T cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect , 2018
Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data , 2020
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set , 2020
Flowcytometric evaluation of cell cycle regulators (cyclins and cyclin dependent kinase inhibitors) expressed on bone marrow cells of patients with chronic myelogenous leukemia and multiple myeloma , 2012
Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant G-CSF , 2000
High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis , 2007
A RAPID DRUG SENSITIVITY ASSAY FOR NEOPLASMATIC CELLS , 1988
Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients , 2012
HLA DR2: A predictive marker in response to cyclosporine therapy in aplastic anemia , 1997
Incidence of Tuberculosis after bone marrow transplantation in a single center from Turkey , 1998
Vitiligo after Hematopoietic Cell Transplantation: Six Cases and Review of the Literature , 2008
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914) , 2001
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk , 2020
Drug Targeting of Genomic Instability in Multiple Myeloma , 2020
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma , 2016
Isatuximab for the treatment of relapsed/refractory multiple myeloma , 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study , 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial , 2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study , 2020
Fetal Cell Microchimerism Normal and Immunocompromised Gestations in Mice , 2020
Prognostic scoring system after transplantation in myeloma: predicting early relapse , 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network , 2020
Drug Targeting of Genomic Instability in Multiple Myeloma , 2020
A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG-PET/CT , 2020
Drug Targeting of Genomic Instability in Multiple Myeloma , 2020
Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma , 2020
Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma , 2020
Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation , 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study , 2020
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) , 2020
Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT , 2020
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma , 2020
Our Treatment Approach to Hairy Cell Leukemia , 2020
The impact of 17 B estradiol level variations on blood lymphocyte counts among healthy females , 2018
Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience , 2018
Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies , 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial , 2019
PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma , 2019
Management of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation , 2014
Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4. , 2016
Randomised unicenter trial for comparison of three regimens inde novo adult acute nonlymphoblastic leukaemia , 1998
Familial Multiple Myeloma Associated with Disorders of Chronic Inflammation: First Report from Turkey , 2008
Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial) , 2016
Lack of Prognostic Value of CD34 in Adult AML , 2009
Hemorrhagic Cystitis as a Complication of Bone Marrow Transplantation , 2013
The effect of G-CSF on lymphocyte subsets and CD34 cells in allogeneic stem cell transplantation , 2001
Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. , 2012
Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM) , 2001
Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF , 2009
Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation , 2001
Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease , 2004
Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). , 2016
Expression of IFITM1 in chronic myeloid leukemia patients , 2005
title Daratumumab plus bortezomib and dexamethasone iversus/i bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR/title , 2018
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. , 2016
Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective , 2011
The impact of the CD34 cell dose on engraftment in allogeneic peripheral blood stem cell transplantation , 1999
Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial) , 2016
IMWG consensus on maintenance therapy in multiple myeloma , 2012
Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up , 2011
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective , 2010
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial , 2010
Filgrastim-Mobilized Peripheral Blood Progenitor Cells Versus Bone Marrow Transplantation For Treating Leukemia: 3-Year Results From The EBMT Randomized Trial , 2005
Hepatitis B virus infection in allogeneic bone marrow transplantation , 1997
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial , 2019
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis , 2019
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients , 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study , 2019
Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide and/or Bortezomib Containing Regimens , 2019
Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 , 2019
Fetal Cell Microchimerism Normal and Immunocompromised Gestations in Mice , 2019
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma , 2019
Bone Marrow Microvessel Density (MVD) in Adult Acute Myeloid Leukemia (AML): Therapy Induced Changes and Effects on Survival , 2009
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow , 2003
Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience , 2018
The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females , 2018
Prenatal diagnosis of organic acidemias at a tertiary center , 2019
Total Blood Lymphocyte Count Alteration During and after Pregnancy , 2017
Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies , 2018
Subsequent malignancies after allogeneic hematopoietic stem cell transplantation , 2017
KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR? , 2018
KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR? , 2018
Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation , 2018
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma , 2017
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study , 2017
Flow Cytometric Aldehyde Dehydrogenase Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem Cell Assessment , 2017
Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial , 2011
CD41 and CD42 hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation , 2001
An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells , 2011
Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations , 2010
Thrombopoietic Cytokines in Patients with Iron Deficiency Anemia with or without Thrombocytosis , 2000
Kronik Lenfositik Lösemi’de Tanı Anında Hipogammaglobulinemi Sağkalım ve Enfeksiyon Riski Üzerine Etklili Midir? , 2018
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement , 2011
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. , 2018
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group , 2011
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group , 2008
Management of treatment-emergent peripheral neuropathy in multiple myeloma , 2012
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) , 2011
Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials , 2011
Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study , 2018
A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis , 2018
Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience , 2018
The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females , 2018
Extracorporeal photochemotherapy in mycosis fungoides , 2017
Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies , 2018
Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipientss? , 2018
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study , 2018
Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
Heparin enhances CD34 content of stem cells collected following G-CSF /- chemotherapy , 2017
Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study , 2017
Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
The safety of bortezomib for the treatment of multiple myeloma , 2018
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network , 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel , 2018
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia , 2001
Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells , 2017
Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study , 2017
The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans , 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 , 2011
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma , 2009
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and ipost-hoc/i analyses on progression-free survival and tumour growth/title , 2017
Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival A Quasi Experimental Study , 2016
Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study , 2017
Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study , 2017
A single center experience with two decades of follow-up on patients with hairy cell leukemia. , 2017
Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia. , 2017
A single center experience with two decades of follow-up on patients with hairy cell leukemia. , 2017
Large unstained cell percentage as a predictor ofefficacious peripheral stem cell mobilization in autologousstem cell transplantation , 2017
Evaluating peritransplant albumin decline as a predictor ofacute graft versus host disease , 2017
Allogeneic hematopoietic stem cell transplantation(allo-HSCT) in advanced age adults: is it possible totransplant safely? , 2017
A Biosimiliar G-CSF filgrastim is as effective as a referencedrug however itis not as cost effectiveas it supposed to beand by the way no impact on the health care system , 2017
Peripheral blood stem cell mobilization and collectionfrom elderly patients (≥65 years) with multiple myeloma: Asingle center experience , 2017
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study , 2017
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial , 2017
Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study , 2017
THE IMPACT OF 17Β ESTRADIOL LEVEL VARIATIONS ON BLOOD LYMPHOCYTE COUNTS AMONG HEALTHY FEMALES , 2017
Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells , 2012
Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic? , 2011
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials , 2012
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma , 2013
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study , 2013
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease , 2013
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma , 2014
High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial , 2014
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study , 2014
Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee , 2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial , 2014
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma , 2014
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma , 2014
HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO) and use of the Luminex™ technology , 2014
Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups , 2015
Effects of in utero cord blood collection on post-cesarean hemoglobin levels , 2015
Impact of “Killer Immunoglobulin-Like Receptor /Ligand” Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival , 2015
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications , 2015
Insight into human protease activated receptor-1 as anticancer target by molecular modelling , 2015
Differences between graft product and donor side effects following bone marrow or stem cell donation , 2003
Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants , 2016
How to Improve Cord Blood Engraftment , 2016
Editorial How to Improve Cord Blood Transplantation By Enhancing Cell Counts or Engraftment , 2016
Flow Cytometrıc Aldehyde Dehydrogenase Aldh Assay Enables A Fast And Accurate Human Umblical Cord Blood Hematopoietic Stem Cell Assessment , 2016
Phase 2 study of tabalumab a human anti B cell activating factor antibody with bortezomib and dexamethasone in patients with previously treated multiple myeloma , 2016
extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft versus host disease , 2017
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone the PANORAMA 1 trial a randomised placebo controlled phase 3 trial , 2016
HLA polymorphism and risk of multiple myeloma , 2016
Daratumumab Bortezomib and Dexamethasone for Multiple Myeloma , 2016
Central nervous system involvement by multiple myeloma A multi institutional retrospective study of 172 patients in daily clinical practice , 2016
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma outcomes by prior treatment , 2016
A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker , 2016
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma results from the EBMT NMAM2000 prospective trial , 2015
Panobinostat a novel pan deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma , 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma , 2015
Panobinostat a novel pan deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma , 2015
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma results from the EBMT NMAM2000 prospective trial , 2015
Antilymphocyte Thymocyte Globulin for the Treatment of Steroid Refractory Acute Graft Versus Host Disease 20 Year Experience at a Single Center , 2015
Analysis of Final Data from the Multinational Non Interventional Observational Emmos Study NCT01241396 in Patients Pts with Multiple Myeloma MM in Real World Clinical Practice , 2015
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma a multicentre randomised double blind phase 3 trial , 2014
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008
International uniform response criteria for multiple myeloma , 2006
HLA A B C DR haplotypes linkeage and frequencies observed inAnkara University Turkey a report from Tran , 2005
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma , 2012
Retrospective matched pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma , 2015
Bildiriler
DAHA ÖNCE YOĞUN TEDAVİ ALMIŞ RELAPS/REFRAKTERMULTİPL MİYELOM HASTALARINDA DARATUMUMABINETKİLİLİK VE GÜVENLİLİĞİ - BEKSAÇ MERAL,aydın yıldız,GÖKER HAKAN,TURGUT MEHMET,kalayoğlu beşışık sevgi,çağırgan seçkin,TUĞLULAR AYŞE TÜLİN,VURAL FİLİZ,YAĞCI ABDULLAH MÜNCİ,ALACACIOĞLU İNCİ,AYTAN PELİN,GÖKSOY HASAN SAMİ,gülbaş zafer,güneş ahmed kürşad,HACIOĞLU SİBEL,kartı sami,KAYNAR LEYLAGÜL,tekgündüz emre
Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience - SEVAL GÜLDANE CENGİZ,ULAŞ BELİZ BAHAR,Taşçı Onur,Özel Fulya,Bulat Buğu,KUZU IŞINSU,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,BEKSAÇ MERAL,İLHAN OSMAN,GÜRMAN GÜNHAN,ARSLAN ÖNDER
Analysis of Beta-catenin Mutations in Acute Myeloid Leukemia. - ALTINOK BUKET,ÖZKAN TÜLİN,KARADAĞ AYNUR,BEKSAÇ MERAL,SUNGUROĞLU ASUMAN
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide - BEKSAÇ MERAL,Delimpasi S.,,ROBAK P.,,Kim K.,,Wilkes J.,fulci giuilia,sule neal,kremer brandon,Dimopoulos MA
External Valıdatıon Of Three Exıstıng Early Myeloma Relapse Scores (By Ebmt, Cıbmtr, And Gımema) In A Sıngle Center Shows Major Dıfferences - BEKSAÇ MERAL, CENGİZ SEVAL GÜLDANE, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, GÜRMAN GÜNHAN
Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study - BEKSAÇ MERAL,Iacobelli Simona,Luuk Gras Luuk,Koster Linda,Baaij Laurien,Hamad Nada,DSouza Anita,Estrada Noel,N Parameswaran,J Andrew,Saber Wael,Iida Minako,Okamoto Shinichiro,Takamatsu Hiroyuki,Mizuno Shohei,Kawamura Koji,Liam Christopher,Goh A Sim,Elhaddad Alaa M.,Bazarbach Ali,Alfar Rozan,Benakli Malek,Riva Eloisa,Galeano Sebastian,Mian Hira,Wang Feng Rong,Lv Meng,Neumann Daniel,Koh Mickey Boon Chai,Snowden John
Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study - BEKSAÇ MERAL,FACON T.,,POUR L.,,HAJEK R.,,K. Liu,Minarik J.,,Moreau, P.,,Jarosinska Joanna Romejko,Vorobyev Vladimir I.,Ishida Tadao,Janowski Wojciech,Parma Gurdeep,Zamagni Elena,Goldschmidt Hartmut,Martin Thomas,Manier Salomon,Orlowski Robert Z.,Comerford Erin,Tian Claire,Msihid Jérôme,BEŞIŞIK SEVGİ
Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial - BEKSAÇ MERAL,Dimopoulos MA,GAY F.,,Ludwig H.,,S. ZWEEGMAN,Petrucci MT,Corradini P.,,LİBERATİ AM,Cavo M.,,Andersen NF,CROOCKEWİT A.,
Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis - BEKSAÇ MERAL,Martin T.,Suzuki K.,,KNAUF W.,Tekle L.,Qiu Y.,
Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) - BEKSAÇ MERAL,DİMOPOULOS MELETİOS A.,Boccadoro M.,,QUACH H.,,HULİN C.,,antonioli elisabetta,LELEU X.,,mangiacavalli silvia,Perrot A.,,Cavo M.,,BROİJL A.,,GAY F.,,MİNA R.,Nijhof N.,,Van de Donk N.W.C.J,Katodritou E.,,Schjesvold F.,,DELFORGE M.,DRİESSEN C.,,HAWKINS JOHN SPENCER,HAJEK R.,,Wang W.,,amorn anna sitthi,boer carla j.,CARSON R.,,Gries KS
Otoimmün Hemolitik Anemi ve T-LGL Birlikteliği Nadir Bir Olgu - ERMİŞ GY, KÖKCÜ G., TOPRAK SELAMİ KOÇAK, BEKSAÇ MERAL, TOPÇUOĞLU PERVİN
Hemofili A ve Multipl Miyelom Tanılı Hastada Otolog Periferik Kök Hücre Mobilizasyonu: Olgu Sunumu - ÇALIŞ U., ERMİŞ GY, YILDIRIM Y.,, CENGİZ SEVAL GÜLDANE, TOPRAK SELAMİ KOÇAK, BEKSAÇ MERAL
Kök hücre toplamada Plerixafor' un yeri: Kemoterapisiz de olur mu? - KARAKAYA B.,, CENGİZ SEVAL GÜLDANE, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, GÜRMAN GÜNHAN, İLHAN OSMAN, BEKSAÇ MERAL, TOPRAK SELAMİ KOÇAK
Myelofibroziste allojenik hematopoetik kök hücre nakli sonuçları: tek merkez deneyimi - SÖNMEZ MEHMET, CENGİZ SEVAL GÜLDANE, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, DEMİRER TANER, GÜRMAN GÜNHAN, İLHAN OSMAN, BEKSAÇ MERAL, ÖZCAN MUHİT
Siklofosfamid ile Mobilizasyonunun Multipl Miyelom Hastalarında Nakil Sonuçlarına Etkileri - GÜVEN M., AKKUŞ ERMAN, CENGİZ SEVAL GÜLDANE, KÖKCÜ G., CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM, BEKSAÇ MERAL, TOPÇUOĞLU PERVİN
Carfilzomib ve Pomalidomid Etkinliğinin Retrospektif Değerlendirilmesi: Ankara Üniversitesi Deneyimi - AKKUŞ ERMAN,MERTER MUSTAFA,ŞAHİN UĞUR,NARLI ÖZDEMİR ZEHRA,ATACA ATİLLA PINAR,TOPÇUOĞLU PERVİN,BEKSAÇ MERAL
Ankara Üniversitesi Tıp Fakültesi Multiple Myelom Elotuzumab ve İmmünmodulatuar İlaç Tedavi Deneyimi - KARAMAN ZEHRA,ŞAHİN UĞUR,MERTER MUSTAFA,GÜNDÜZ MEHMET,ÖZEN MEHMET,BEKSAÇ MERAL
Clonal Plasma Cell Detection by High Sensitive Flow Cytometry in Aphaeresis Product is Poor Prognostıc and not Increased by Use of Plerixafor Alone - CENGİZ SEVAL GÜLDANE,USLU A,,DALVA KLARA,BAKANAY SM,MERTER MUSTAFA,ŞAHİN UĞUR,İLHAN OSMAN,BEKSAÇ MERAL
Evaluating peritransplant albumin decline as a predictor of acute graft versus host disease - MERTER MUSTAFA,YÜKSEL MELTEM,demir en,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
Large unstained cell percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation - MERTER MUSTAFA,Köken K,YÜKSEL MELTEM,Demir EN,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL
A prospective analysis on the frequency and predictive value of minimal residual disease assessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance - BEKSAÇ MERAL,CENGİZ SEVAL GÜLDANE,ŞAHİN UĞUR,MERTER MUSTAFA,İPEK ŞENAY,ÖZKAN ELGİN,DALVA KLARA
A Preliminary Analysis of Inherited Immune Checkpoint Control in Multiple Myeloma: Relative Frequency of Inhibitory or Activating Type Killer Immunoglobulin like Receptors and Their Cognate Ligands HLA-C1 and -C2 - BEKSAÇ MERAL, YURDAKUL PINAR, AKIN H. YALIM, AYDIN GOZDE, BUNSUZ ŞENGÜN MERVE, ŞAHİN UĞUR, MERTER MUSTAFA, DALVA KLARA
Residual Clonal Plasma Cells Detected by Flow Cytometry at 10-4 Level within Autologous Stem Cell Grafts is Associated with Significantly Less Overall Survival - CENGİZ SEVAL GÜLDANE,DALVA KLARA,BAKANAY SM,,MERTER MUSTAFA,ŞAHİN UĞUR,USLU ATİLLA,ÖZTÜRK CEMALETTİN,İLHAN OSMAN,BEKSAÇ MERAL
Multipl Miyelom Olgularında Otolog Kök Hücre Naklinde Yüksek Doz Melfelana Bortezomib Eklenmesinin Tek Merkez Sonuçları - CENGİZ SEVAL GÜLDANE,KOYUN DERYA,KIRCALİ EKİN,ŞAHİN UĞUR,TOPRAK SELAMİ KOÇAK,ÖZCAN MUHİT,BEKSAÇ MERAL
Plerixafor, Periferik Kök Hücre Ürününde Akım Sitometri İle Saptanabilen Klonal Plazma Hücre Kontaminasyonunu Etkiler Mi? - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,DALVA KLARA,BAKANAY ÖZTÜRK ŞULE MİNE,MERTER MUSTAFA,ŞAHİN UĞUR,İLHAN OSMAN,BEKSAÇ MERAL
The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence - DALVA KLARA,CENGİZ SEVAL GÜLDANE,OZ dilek,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,Alnıaçık EZGİ,ALTAN HİLAL,ALNIAÇIK RIDVAN,SERTEL SUAT,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Can Nelarabıne Rescue The Graft After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon In T-All ? - YÜKSEL MELTEM,CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN,GÜRMAN GÜNHAN
Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation - CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL
Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset - AKIN HY, CENGİZ SEVAL GÜLDANE, ATİLLA PA, YURDAKUL MESUTOĞLU PINAR, TANER OTLU, ALNIAÇIK R.,, DALVA KLARA, GÜRMAN GÜNHAN, BEKSAÇ MERAL
Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation - CENGİZ SEVAL GÜLDANE, DALVA KLARA, ÖZ MEMNUNE DİLEK, ÖZTÜRK SMB, SOYDAN E.,, GÜRMAN GÜNHAN, İLHAN OSMAN, BEKSAÇ MERAL
A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm - ÖZCAN MUHİT,KOYUN DERYA,CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KIRCALİ EKİN,ÖZTÜRK CEMALETTİN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,İLHAN OSMAN,BEKSAÇ MERAL
Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients? - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis - CENGİZ SEVAL GÜLDANE,ÖZTÜRK N,,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells - AKIN HY,TURASAN E,,KIRCALİ E,,AKKUŞ ERMAN,CENGİZ SEVAL GÜLDANE,YURDAKUL MESUTOĞLU PINAR,DALVA KLARA,BEKSAÇ MERAL
Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KIRCALİ E,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,DALVA KLARA,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
A retrospective single center experience with the generic of lenalidomide Rivelime (R) compared with original patented drug Revlimid (R) - BEKSAÇ MERAL,CENGİZ SEVAL GÜLDANE,KOYUN DERYA,TOPÇUOĞLU PERVİN,YÜKSEL MELTEM,GÜRMAN GÜNHAN,İLHAN OSMAN
Is post-transplant albumin a predictor of early transplant complications? - TOPÇUOĞLU PERVİN,CENGİZ SEVAL GÜLDANE,AKKUŞ ERMAN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Ruxolitinib in steroid refractory GVHD treatment: single center experience - CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,BEKSAÇ MERAL
Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen - İLHAN OSMAN, CENGİZ SEVAL GÜLDANE, USLU ATİLLA, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, AKAN HAMDİ, BEKSAÇ MERAL, GÜRMAN GÜNHAN
Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma - CENGİZ SEVAL GÜLDANE,SERTESEN ELİF,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
Results Of A Sıngle Center Experıence: An Attempt To Augment Condıtıonıng Regımen In Fırst Autologous Stem Cell Transplantatıon - CENGİZ SEVAL GÜLDANE,KOYUN D,,KİRCALİ E,,TOPRAK SELAMİ KOÇAK,ÖZCAN MUHİT,BEKSAÇ MERAL
Is mobilization with chemotherapy effect response in the multiple myeloma? - CENGİZ SEVAL GÜLDANE,USLU A,,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPÇUOĞLU PERVİN
Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,USLU A,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Treatment Of Thrombocytopenıa After Allogeneıc Stem Cell Transplantatıonwıth Eltrombopag - KIRCALİ EKİN, CENGİZ SEVAL GÜLDANE, KOYUN DERYA, ÖZTÜRK CEMALETTİN, USLU ATİLLA, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, AKAN HAMDİ, İLHAN OSMAN, GÜRMAN GÜNHAN, BEKSAÇ MERAL, YÜKSEL MELTEM
Flamsa-Based Hıgh-Dose Sequentıal Condıtıonıng Regımen Followed By Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allo-Hsct): Is It Effectıveın Patıents Wıth Prımary Refractory Or Relapsed Acute Leukemıa? - CENGİZ SEVAL GÜLDANE,EKİN KIRCALİ,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPÇUOĞLU PERVİN
The Influence Of Antı-Thymocyte Globulın (Atg) On The Outcomes Of Patıents Wıth Aml W/Wo Measurable Resıdual Dısease (Mrd) At The Tıme Of Unrelated Donor Transplantatıon - CENGİZ SEVAL GÜLDANE, KIRCALİ EKİN, BALTACI MEHMET AKİF, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, DALVA KLARA, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, GÜRMAN GÜNHAN, İLHAN OSMAN, AKAN HAMDİ, BEKSAÇ MERAL, TOPRAK SELAMİ KOÇAK
Role Of Chımerısm And Flow-Cytometrıc Monıtorıng Of Measurable Resıdualdısease (Mrd) After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allohsct) In Predıctıng Relapse In Acute Myeloıd Leukemıa (AML) - CENGİZ SEVAL GÜLDANE, ULAŞ ELİZ BAHAR, TOPRAK SELAMİ KOÇAK, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, DALVA KLARA, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, AKAN HAMDİ, BEKSAÇ MERAL, GÜRMAN GÜNHAN
Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KİRCALİ EKİN,CİVRİZ BOZDAĞ SİNEM,DALVA KLARA,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,KUZU IŞINSU,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia? - KIRCALİ EKİN,CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPÇUOĞLU PERVİN
Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis - CENGİZ SEVAL GÜLDANE,ÖZTÜRK NERGİS,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs - CENGİZ SEVAL GÜLDANE,KUZU IŞINSU,YÜKSEL SEHER,KAYGUSUZ GÜLŞAH,DALVA KLARA,ÖZCAN MUHİT,BEKSAÇ MERAL
Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic - BEKSAÇ MERAL, TUĞLULAR T.,, ÜNAL A.,, Cavo M.,, Gay Francesca, KATODRITOU EIRINI, ÖZSAN GÜNER HAYRİ, CENGİZ SEVAL GÜLDANE, SEVİNDİK ÖMÜR GÖKMEN, Merante Serena, Manousou Kyriaki, Sonneveld P.,, Terpos E.,
KILLER IMMUNOGLOBULIN LIKE HAPLOTYPE BB IS OBSERVED MORE FREQUENTLY AMONG MYELOMA CASES COMPARED TO HEALTHY CONTROLS - AKIN Hasan Yalım, ATACA ATİLLA PINAR, YURDAKUL MESUTOĞLU PINAR, CENGİZ SEVAL GÜLDANE, OTLU TANER, ALNIAÇIK R.,, DALVA KLARA, GÜRMAN GÜNHAN, BEKSAÇ MERAL
CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION - YÜKSEL MELTEM,KIRCALI EKİN,CENGİZ SEVAL GÜLDANE,KOYUN DERYA,USLU ATİLLA,ÖZTÜRK CEMALEDDİN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,BEKSAÇ MERAL,ÖZCAN MUHİT,İLHAN OSMAN,ARSLAN ÖNDER,AKAN HAMDİ,DEMİRER TANER,GÜRMAN GÜNHAN
LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN
CAN AUTOLOGOUS STEM CELL TRANSPLANTATIONABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH? - CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
Yurt İçi Ve Yurt Dışı Gönüllü Akaraba Dışı Vericilerde HLA Özdeşlik Durumu : 10/10 >9/10 Mu Yoksa En Büyük HLADPB1 Mi? - YÜKSEL MELTEM, CENGİZ SEVAL GÜLDANE, DALVA KLARA, CEYLAN G.,, AKAL F.,, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, GÜRMAN GÜNHAN, BEKSAÇ MERAL
Evaluation of chemokine reseptor 4 expression by 68Ga Pentixafor PET/CT in patients with multiple myeloma - ÖZKAN ELGİN, SOYDAL ÇİĞDEM, ŞAHİN UĞUR, KÜÇÜK NURİYE ÖZLEM, BEKSAÇ MERAL, ÖZTÜRK CEMALEDDİN, TOPÇUOĞLU PERVİN, KROPF SASKIA, HANS JURGEN WESTER
Large Unstained Cell Percentage as a Predictor of Efficacious Peripheral Stem Cell Mobilization - MERTER MUSTAFA,KÖKEN KÜBRA,YÜKSEL MERVE,NURDAN DEMİR ELİF,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,YÜKSEL MELTEM
A biosimilar G-CSF filgrastim is as effective as a reference drug, however, it is not as cost effective as it supposed to be - PEKCAN GÜLTEKİN, KURT YÜKSEL MELTEM, ŞAHİN UĞUR, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, İLHAN OSMAN, DEMİRER TANER, GÜRMAN GÜNHAN, BEKSAÇ MERAL
Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler - Aydın Tolga,MERTER MUSTAFA,ŞAHİN UĞUR,Pekcan Gültekin,NARLI ÖZDEMİR ZEHRA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN,YÜKSEL MELTEM
Evaluation of chemocine reseptor 4 expression by 68Ga pentixafor PET/CT in patients with multiple myeloma - ÖZKAN ELGİN,SOYDAL ÇİĞDEM,ŞAHİN U,KÜÇÜK NURİYE ÖZLEM,BEKSAÇ MERAL,ÖZTÜRK C,CİVRİZ BOZDAĞ SİNEM,TOPÇUOĞLU PERVİN
Treatment with BiTEs: Is it the new standard for penta-refractory patients? - BEKSAÇ MERAL
Response in Multiple Myeloma - BEKSAÇ MERAL
Therapy of elderly patients - BEKSAÇ MERAL
Multiple Miyelom - BEKSAÇ MERAL
Scoring system for Auto-HCT: feasibility in MM patients - BEKSAÇ MERAL
Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch–Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network - MAİ EK, HİELSCHER T.,, ZWEEGMAN S.,, BEKSAÇ MERAL, Dimopoulos MA, WEİSEL K.,, Cavo M.,, Sonneveld P.,, GOLDSCHMİDT H.,
Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease - RİCHTER J.,, Laubach JP, STRİCKER S.,, Schjesvold FH, COHAN D.,, SUREDA A.,, MARANDA EL, BEKSAÇ MERAL, Dimopoulos MA, CHARİ A.,, Richardson PG, Moreau P.,
Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study - Comenzo R.,, Palladini G.,, Kastritis E.,, Minnema MC, Wechalekar AD, Jaccard A.,, Dispenzieri A.,, Schonland S.,, Cibeira MT, BEKSAÇ MERAL, Hungria V.,, Vermeulen J.,, Merlini G.,
Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT - GAGELMANN N.,, Eikema DJ, KOSTER L.,, NETELENBOS T.,, McDonald A.,, STOPPA AM, Anagnostopoulos A.,, BEKSAÇ MERAL, Schonland S.,, Yakoub-Agha I.,
Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study - Sonneveld S.,, Terpos E.,, Boccadoro M.,, Delimpasi S.,, BEKSAÇ MERAL, Katodritou E.,, Mateos MV, Dimopoulos MA
A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party - BEKSAÇ MERAL, LACOBELLİ S.,, KOSTER L.,, Cornelissen JJ, Griskevicius L.,, Engelhardt M.,, Elmaagacli A.,, Hayden A.,, Schonland S.,, Yakoub-Agha I.,
Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE) - KİM K.,, Schutz NP, YEH SP, VERBURGH E.,, INT M.,, Alsharif F.,, Wu C.,, WAN H.,, HUANG Z.,, BEKSAÇ MERAL
Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO. - Terpos E.,, Dimopoulos MA, Boccadoro M.,, Delimpasi S.,, BEKSAÇ MERAL, Katodritou E.,, Moreau P.,, Baldini L.,, Mateos MV, Einsele H.,, Sonneveld P.,
Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial - WEİSEL K.,, Dimopoulos MA, Oriol A.,, BEKSAÇ MERAL, Dimopoulos F.,, LİBERATİ AM, Andersen LD, LAROCCA A.,, GROTE T.,, PELUSO T.,, Richardson PG
Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma - CHARİ A.,, Dimopoulos MA, BEKSAÇ MERAL, LELEU X.,, WEİSEL K.,, RİCHTER J.,, DİRNBERGER F.,, İSKANDER K.,, Yusuf A.,, MİKHAEL J.,
The Role Of Upfront Autotransplantatıon And Consolıdatıon Therapy In Newly Dıagnosed Multıple Myeloma (Ndmm): Fınal Analysıs Of The Randomızed Phase 3 Emn02/Ho95 Study - Cavo M.,, GAY F.,, BEKSAÇ MERAL, Dimopoulos MA, PANTANİ L.,, ZWEEGMAN S.,, ZAMAGNİ E.,, PALUMBO GA, Zambello R.,, Andersen NF, Boccadoro M.,, Sonneveld P.,
Immunoglobulin V(D) J Recombination, Protein Ubiquitination, Cell Adhesion and Sonic Hedgehog Gene Variants are detected among familial Multiple Myeloma subjects following whole exome sequencing - AKKUŞ E.,, TİMUR T.,, AYDIN Y.,, BEŞIŞIK SK, GURKAN E.,, RATİP S.,, SALİHOĞLU A.,, SARGIN D.,, A., UNAL, TURCAN A.,, BEKSAÇ MERAL
Trends in Autologous Stem Cell Mobilisation Practices in Myeloma Patients in Ebmt Centers Between 2008 And 2017 - DİLLON J.,, Hayden PJ, Eikema DJ, KOSTER L.,, Blaise D.,, HUANG H.,, BEKSAÇ MERAL, Schonland S.,, Yakoub-Agha I.,
Autologous Hematopoietic Cell Transplantation For Relapsed Multiple Myeloma Performed With Stem Cells Re-Mobilised Following A Prior AUTO-HCT - A Retrospective Study on Behalf of EBMT CMWP - Drozd-Sokolowska J.,, GRAS L.,, ZİNGER N.,, MUTLU ARAT, BAŞAK G.,, GÜRMAN GÜNHAN, Hayden P.,, BEKSAÇ MERAL, Schonland S.,, Yakoub-Agha I.,
Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients - KIRCALİ EKİN, SEVAL GÜLDANE CENGİZ, ÖZTÜRK C.,, BOZDAĞ S.C., YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, GÜRMAN GÜNHAN, BEKSAÇ MERAL
Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM) - Richardson pg, Perrot A.,, San-Miguel J.,, BEKSAÇ MERAL, LELEU X., Anderson KC
Multipl Miyelomda Otolog Priferik Kök Hücre Nakli Sonrası Erken Nüksü Belirlemede CIBMTR, ISS ve R-ISS Skorlama Sistemlerinin Karşılaştırılması - SEVAL GÜLDANE CENGİZ, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, GÜRMAN GÜNHAN, BEKSAÇ MERAL
SUBCUTANEOUS DARATUMUMAB ± BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE in patients with newly diagnosed light chain amyloidosis: Updated results from the phase 3 andromeda study - Kastritis E.,, Sanchorawala V.,, Palladini G.,, Minnema MC, Wechalekar AD, Jaccard A.,, Dispenzieri A.,, Lee HC, Bhutani D.,, Gibbs S.,, Mollee P.,, Venner C.,, Lu J.,, Schönland S.,, Gatt M.,, Suzuki M.,, Kim K.,, Cibeira MT, BEKSAÇ MERAL, Libby E.,, Valent J.,, Hungria V.,, Wong SW, Rosenzweig M.,, Bumma N.,, Chauveau D.,, Tran N.,, Qin X.,, Vasey S.Y.,, Tromp B.,, Weiss W.,, Vermeulen J.,, Comenzo RL., Merlini G.,
Molecular Alterations Obtained by High Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targetted Therapies - KUZU IŞINSU, SEVAL GÜLDANE CENGİZ, YÜKSEL S.,, Kaygusuz G.,, DALVA KLARA, ÖZCAN MUHİT, BEKSAÇ MERAL
Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO. - Terpos E.,, Dimopoulos MA, Boccadoro M.,, Delimpasi S.,, BEKSAÇ MERAL, Katodritou E.,, Moreau P.,, Baldini L.,, Symeonidis A.,, Bila J.,, Oriol A.,, Mateos MV, Einsele H.,, Orfanidis L.,, Gries KS, Fastenau J.,, Kampfenkel T.,, Qiu Y.,, Amin H.,, Sonneveld P.,
Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). - Richardson PG.,, Perrot A.,, San-Miguel J.F.,, BEKSAÇ MERAL, Spicka I.,, Cavo M.,, Prince M.,, Zheng C.,, Dubin F.,, Van De Velde H.,, Anderson K.C.,
Assocıatıon Of Reduced Absolute İflc And Dflc Wıth Prolonged Major Organ Deterıoratıon Progressıon-Free Survıval In Patıents Wıth Newly Dıagnosed Al Amyloıdosıs Receıvıng VCD Wıth Or Wıthout Daratumumab: Results From Andromeda - Kastritis E.,, Comenzo R.,, Minnema MC, Wechalekar A.,, Jaccard A.,, Sanchorawala W.,, Lee H.C.,, Gibbs S.,, Mollee P.,, Venner CP, Schoenland S.,, BEKSAÇ MERAL, Bumma N.,
Melfelan Hazırlık Rejimi Tek Gün Ve İki Gün Kullanımı Yan Etki Değerlendirmesi, Fark Var Mı ? - Öztürk N.,, BEKLER İ.,, ERDEMSOY B.,, ŞEN T.,, SEVAL GÜLDANE CENGİZ, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, BEKSAÇ MERAL, GÜRMAN GÜNHAN, YÜKSEL MELTEM
In Vitro Semisolid Agar Veya Sıvı Kültür Koşullarında Vpa Ve Nam Gibi Küçük Moleküller Aracılığı İle Hematopoietik Kök Hücre Ekspansiyonu Kinetikleri - DALVA KLARA, AKIN Hasan Yalım, ÖNCÜL EMİNE BEGÜM GENCER, TURASAN EYLÜL, YOUSEFZADEH MAHSA, ŞEKER E.,, SÜT HASAN, ÇAĞAN M.,, YURDAKUL MESUTOĞLU PINAR, BEKSAÇ MERAL
Fare-İnsan Xenograft Hematopoietik Kök Hücre Nakli Modelinde Vpa Ve/Veya Nam İle Ekspande Edilmiş Hematopoietik Kök Hücrelerin Engrafman Kinetikleri - TURASAN EYLÜL, ÖNCÜL EMİNE BEGÜM GENCER, AKIN Hasan Yalım, YOUSEFZADEH MAHSA, ÇAĞAN M.,, SEVAL M.,, DALVA KLARA, YURDAKUL MESUTOĞLU PINAR, BEKSAÇ MEHMET SİNAN, BEKSAÇ MERAL
Solid Organ Nakli Ve Allojenik Kök Hücre Nakli Sonrası Gelişen Post-Transplant Lenfoproliferatif Hastalık- Tek Merkez Deneyimi - Öztürk C.,, KIRCALİ EKİN, KOYUN DERYA, YILMAZ H.,, YAVUZ G.,, KARAKAYA B.,, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, GÜRMAN GÜNHAN, BEKSAÇ MERAL, CİVRİZ BOZDAĞ SİNEM, İLHAN OSMAN
Relaps/Refrakter Hodgkin Lenfoma Hastalarında Allojenik Hematopoetik Kök Hücre Nakli: Tek Merkez Deneyimi - KOYUN D.,, ŞAHİN U.,, SEVAL GÜLDANE CENGİZ, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, DEMİRER TANER, BEKSAÇ MERAL, İLHAN OSMAN, GÜRMAN GÜNHAN, ÖZCAN MUHİT
Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University - SEVAL GÜLDANE CENGİZ, BOZDAĞ S.C., TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, TUNCALİ T.,, GÜRMAN GÜNHAN, BEKSAÇ MERAL
Treatment of Patients With Relapsed/Refractory Multiple Myeloma With Pomalidomide and Dexamethasone With or Without Subcutaneous Daratumumab: Patient-Reported Outcomes From APOLLO - Dimopoulos MA, Terpos E.,, Boccadoro M.,, Delimpasi S.,, BEKSAÇ MERAL, Katodritou E.,, Moreau P.,, Baldini L.,, Mateos MV, Einsele H.,, Orfanidis I.,, Sonneveld P.,
Large Unsatained Cell (LUC) percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation - MERTER MUSTAFA,KÖKEN KÜBRA,YÜKSEL MERVE,DEMİR NURDAN,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,YÜKSEL MELTEM
Heparin enhances CD34 content of stem cells collected following G-CSF +/- chemotherapy - MERTER MUSTAFA,ŞAHİN UĞUR,YILDIRIM Y,,İLHAN OSMAN,BEKSAÇ MERAL
A Biosimiliar G-CSF filgrastim is as effective as a reference drug however it is not cost effective as supposed to be and by the way no impact on the health care system - YÜKSEL MELTEM,PEKCAN GÜLTEKİN,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,GÜRMAN GÜNHAN,BEKSAÇ MERAL
Evalauting peritransplant albümin decline as a predictor os acute graft versus host disease - MERTER MUSTAFA,YÜKSEL MELTEM,NURDAN DEMİR ELİF,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
Condıtıonıng Wıth Bortezomıb-Mel200 In Comparıson To Mel200 Improves Survıval Among Myeloma Patıents In≤Pr Prıor To Auto-Hct: A Study From The Cmwp Of The Ebmt - BEKSAÇ MERAL,Eikema DJ,Chevallier P,,Hulin C,,Orchard K,,Mohty M,,Hamladji RM,Spyridonidis A,,Schönland S,,Agha IY
Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95) - Sonneveld P,,BEKSAÇ MERAL,Holt BVD,Dimopoulos MA,Carella AM,Ludwig H,,Zweegman S,,Wester R,,Hajek R,,L, Pantani,Fioritoni F,,Mellqvist UH,Troia R,,Andersen NF,Wu KL,Carvalho S,,Croockewit AJ,Schjesvold F,,Offidani M,,M, Cavo,Boccadoro M,
Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type A Study from the Chronic Malignancies Working Party of the EBMT - Sahebi F,,Eikema DJ,Koster L,,Meijer E,,Angelucci E,,Tarella D,,McDonald A,,BEKSAÇ MERAL,S, Schonland
Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda - Comenzo RL,Kastritis E,,Palladini G,,Minnema MC,Wechalekar AD,Jaccard A,,Sanchorawala V,,Mollee P,,Venner CP,,Schönland S,,Gatt M,,Suzuki K,,Cibeira MT,BEKSAÇ MERAL,Libby E,,Valent J,,Hungria VTM,Wong SW,Rosenzweig M,,Chauveau D,,Dimopoulos MA,Vasey SY,Tromp B,,Weiss BM,Vermeulen J,,Merlini G,
Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT - Vincent L,,Ceballos P,,J, Finke,Passweg J,,Minnema MC,Ducastelle S,,Schroyens W,,Zuckerman T,,Ladetto M,,BEKSAÇ MERAL
Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study - Sanchorawala V,,Palladini G,,Minnema MC,Jaccard A,,BEKSAÇ MERAL,Hungria VTM,Rosenzweig M,,Vermeulen J,,Wechalekar AD
Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Soft-Tissue Plasmacytomas: Icaria-MM Subgroup Analysis - BEKSAÇ MERAL,Richardson PG,Unal A,,Corradini P,,DeLimpasi S,,Z, Gulbas,Kerridge IH,Symeonidis A,,Bringhen S,,Moreau P,,Spicka I,
Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Dimopoulos MA,Terpos E,,Boccadoro M,,Delimpasi S,,BEKSAÇ MERAL,Katodritou E,,P, Moreau,L, Baldini,A, Symeonidis,Oriol A,,Mateos MV,Einsele H,,Orfanidis I,,Ahmadi T,,Ukropec J,,Kampfenkel T,,Schecter J,,Qiu Y,,Amin H,,Vermeulen J,,Carson J,,Sonneveld P,
Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study - Laubach JP,Schjesvold F,,Mariz M,,Dimopoulos MA,Marada EL,Spicka I,,Hungria VTM,Shelekhova T,,Abdo A,,Jacobasch L,,BEKSAÇ MERAL,Goncalves I,,Lonial S,,Spencer A,,Blanche PM,Moreau P,,Richardson PG,SanMiguel JF
Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study - Cavo M,,Gay F,,BEKSAÇ MERAL,Dimopoulos MA,Pantani L,,Petrucci MT,Dozza L,,Maisnar V,,Hansson M,,Belotti A,,Pour L,,Ypma PF,M, Grasso,Croockewit S,,Musto P,,Ludwig H,,Morelli AM,Hajek R,,Driessen U,,Gimsing P,,Mellqvist UH,Zander T,,Boccadoro M,,Sonneveld P,
Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized PANORAMA 3 Study - Laubach JP,Schjesvold F,,Mariz M,,Dimopoulos MA,LechMaranda E,,Spicka I,,Hungria VTM,Shelekhova T,,Abdo A,,Jacobasch L,,Polprasert C,,Hajek R,,Illes A,,Wrbel T,,Sureda A,,BEKSAÇ MERAL,Gonçalves IZ,Creixenti JB,Rajkumar SV,Chari A,,Lonial S,,Spencer A,,Moreau P,,Richardson PG,JF SanMiguel
Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies - KUZU IŞINSU,CENGİZ SEVAL GÜLDANE,YÜKSEL MELTEM,KAYGUSUZ GÜLŞAH,DALVA KLARA,ÖZCAN MUHİT,BEKSAÇ MERAL
LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTEMYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS -A RETROSPECTIVE STUDY FROM A TERTIARY CENTER - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN
A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm - ÖZCAN MUHİT,KOYUN DERYA,CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KIRCALİ EKİN,ÖZTÜRK CEMALETTİN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,İLHAN OSMAN,BEKSAÇ MERAL
Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001 - Leleu X,,BEKSAÇ MERAL,Chou T,,Dimopoulos MA,Yoon SS,Prince HM,Pour L,,Shelekhova T,,Chari A,,Khurana M,,Obreja M,,Qi M,,Oriol A,,Samuel D,,Siegel D,
Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001 - Leleu X,,BEKSAÇ MERAL,Chou T,,Dimopoulos MA,Yoon SS,Prince HM,Pour L,,Shelekhova T,,Chari A,,Khurana M,,Obreja M,,Qi M,,Oriol A,,Samuel D,,Siegel D,
Pomalıdomıde, Bortezomıb, Dexamethasone After 1 Prıor Lıne Of Therapy In Patıents Wıth Relapsed Or Refractory Multıple Myeloma And Renal Impaırment: Optımısmm Subanalysıs - Schjesvold F,,Dimopoulos MA,BEKSAÇ MERAL,Oriol A,,Lindsay J,,Liberati AM,Galli M,,Robak P,,Weisel K,,Larocca A,,Yagci M,,Vural F,,Anderson LD,Kanate AS,Casal E,,Jiang R,,Srinivasan S,,Grote L,,Biyukov T,,Richardson P,
Pomalıdomıde, Bortezomıb, Dexamethasone After 1 Prıor Lıne Of Therapy In Patıents Wıth Relapsed Or Refractory Multıple Myeloma And Renal Impaırment: Optımısmm Subanalysıs - Schjesvold F,,Dimopoulos MA,BEKSAÇ MERAL,Oriol A,,Lindsay J,,Liberati AM,Galli M,,Robak P,,Weisel K,,Larocca A,,Yagci M,,Vural F,,Anderson LD,Kanate AS,Casal E,,Jiang R,,Srinivasan S,,Grote L,,Biyukov T,,Richardson P,
Isatuxımab Plus Pomalıdomıde And Dexamethasone In Patıents Wıth Relapsed/Refractory Multıple Myeloma And Soft-Tıssue Plasmacytomas: Icarıa-Mm Subgroup Analysıs - BEKSAÇ MERAL,Richardson PG,Unal A,,Corradini P,,DeLimpasi S,,Gulbas Z,,Kerridge I,,Mikala G,,Neylon A,,Symeonidis A,,Bringhen S,,Moreau P,,Velde H,,Campana F,,Guennec SL,I, Spicka
Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. - Durie BG,Moreau P,,Sonneveld P,,BEKSAÇ MERAL,Kumar S,
Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial) - Sonneveld P,,BEKSAÇ MERAL,Dimopoulos MA,Ludwig H,,Driessen C,,Wester R,,Hajek R,,S, Croockewit
Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial) - Sonneveld P,,BEKSAÇ MERAL,Dimopoulos MA,Ludwig H,,Driessen C,,Wester R,,Hajek R,,S, Croockewit
Risk assessment at diagnosis and risk based therapy - BEKSAÇ MERAL
Update on multiple myeloma - BEKSAÇ MERAL
Monoclonal Antibodies in Newly Diagnosed Multiple Myeloma: New Trials and Combinations - BEKSAÇ MERAL
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. - Palumbo A,,Weisel K,,Nooka AK,BEKSAÇ MERAL,Spicka I,,VTM Hungria,Mateos MA,TM Mark
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. - Palumbo A,,Weisel K,,Nooka AK,BEKSAÇ MERAL,Spicka I,,VTM Hungria,Mateos MA,TM Mark
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. - Palumbo A,,Weisel K,,Nooka AK,BEKSAÇ MERAL,Spicka I,,VTM Hungria,Mateos MA,TM Mark
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. - Palumbo A,,Weisel K,,Nooka AK,BEKSAÇ MERAL,Spicka I,,VTM Hungria,Mateos MA,TM Mark
TREATMENT OF MYELOMA:MAİNTENANCE STRATEGY - BEKSAÇ MERAL
İnternational representative - BEKSAÇ MERAL
Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients community-based trial data - BEKSAÇ MERAL
Double ASCT: Suitable for all patients - BEKSAÇ MERAL
The viewpoint of Scientific Groups: Part 2 - BEKSAÇ MERAL
Current Immunotherapies - BEKSAÇ MERAL
Myeloma - BEKSAÇ MERAL
Relapsed myeloma - BEKSAÇ MERAL
Multiple Myeloma - BEKSAÇ MERAL
Türkiye’de erişilebilir yeni tedaviler ve klinik araştırmalar - BEKSAÇ MERAL
Multıple Myeloma ve Plazma Hücre Hastalıkları - BEKSAÇ MERAL
Multiple Myeloma - the Best Therapy for newly diagnosed patients in 2019 - BEKSAÇ MERAL
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) - Richardson PG,Attal M,,Rajkumar SV,San Miguel J,,BEKSAÇ MERAL,Spicka I,,Leleu X,,Schjesvold F,,Moreau P,,Dimopoulos MA,Huang JSY,Minarik J,,Cavo M,,Prince HM,Mace S,,Corzo KP,Campana F,,LeGuennec S,,Dubin F,,Anderson KC
Analysis of outcomes in patients with myeloma who had a second allohct EITHER for disease relapse or graft failure: AN EBMT CMWP study - Hayden P,,Eikema DJ,de Wreede L,,Koster L,,Kroger N,,Einsele H,,Petersen E,,Angelucci E,,Potter M,,Passweg J,,Espiga CR,Leblond V,,Platzbecker U,,Tischer J,,Ciceri F,,Veelken JH,Ljungman P,,Schaap N,,Milpied N,,Carella AM,Gandemer V,,Arcese W,,Bloor A,,Olivieri A,,Vincent L,,BEKSAÇ MERAL,Schonland S,,YakoubAgha I,
Multiple myeloma treatment in real-world clinical practice: A focus on induction regimens prior to autologous stem cell transplantation from the prospective, multinational, non-interventional emmos study - Mohty M,,Terpos E,,Mateos MV,Cavo M,,Lejniece S,,BEKSAÇ MERAL,Legiec W,,Bekadja MA,M, Dimopoulos,Stankovic S,,Duran MS,De Stefano V,,Corso A,,Kochkareva Y,,Laane E,,Berthou C,,Salwender H,,Masliak Z,,Peceliunas V,,Willenbacher W,,Silva J,,Louw V,,Nemet D,,Borbenyi Z,,Abadi U,,Pedersen RS,Cernelc P,,Potamianou A,,Couturier C,,Feys C,,ThoretBauchet F,,Boccadoro M,
Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT - Schönland SO,Iacobelli S,,Koster L,,Blaise D,,Potter M,,Cornelissen JJ,Chevallier P,,Mayer J,,Remnyi P,,Gribben JG,Meijer E,,Carpenter B,,Collin MP,GeddeDahl T,,Potter V,,Malladi R,,Stelljes M,,Bloor A,,TUĞLULAR AYŞE TÜLİN,Weissinger F,,BEKSAÇ MERAL,Hayden PJ,YakoubAgha I,,Kröger N,
A Phase 3 Randomızed, Open-Label, Multıcenter Study Of Isatuxımab, Pomalıdomıde, And Low-Dose Dexamethasone Vs Pomalıdomıde And Low-Dose Dexamethasone In Relapsed/Refractory Multıple Myeloma (Rrmm) - Attal M,,Richardson PG,Rajkumar SV,SanMiguel J,,BEKSAÇ MERAL,Spicka I,,Leleu X,,Schjesvold F,,Moreau P,,Dimopoulos MA,Huang JSY,Minarik J,,Cavo M,,Prince HM,Mace S,,Corzo KP,Campana F,,LeGuennec S,,Dubin F,,Anderson KC
Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial - Dimopoulos MA,Weisel K,,Lonial S,,White D,,Moreau P,,Mateos MV,SanMiguel J,,Anderson KC,O, Shpilberg,Grosicki S,,Spicka I,,WalterCroneck A,,Magen H,,Belch A,,Reece D,,BEKSAÇ MERAL,Ganetsky A,,Jou YM,McKiver MP,Singhal AK,Richardson PG
Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) - BEKSAÇ MERAL,zamagni e,,TM MARK,NANNİ C,,JAGANNATH S,
RETROSPECTIVE ANALYSIS OF 149 UNSELECTED PATIENTSWITH MANTLE CELL LYMPHOMA CONFIRMS PROGNOSTICRELEVANCE OF MIPI: SINGLE CENTER EXPERIENCE - SEVAL GÜLDANE CENGİZ,ULAŞ BELİZ BAHAR,bolat bugu,Taşçı Onur,karatepe fulya,KUZU IŞINSU,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,ARSLAN ÖNDER
Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients – the Diadem Study from the Chronic Malignancies Working Party of the EBMT - Anna WG,Wang J,,Wreede LC,Sirait T,,ÖZKURT ZÜBEYDE NUR,Snowden JA,Dreger P,,Ills A,,ARAT MUTLU,Bulabois CE,Baurmann H,,Sever M,,Basak GW,Nikolousis M,,Potter V,,Schroyens W,,Gyan E,,Gorkom GV,Serna J,,Guffroy B,,Hayden PJ,BEKSAÇ MERAL,Schönland SO,YakoubAgha I,
Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT? - YÜKSEL MELTEM,CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KIRCALI EKİN,ÖZTÜRK CEMALEDDİN,NARLI ÖZDEMİR ZEHRA,CINAR GÜLE,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AZAP ALPAY,AKAN HAMDİ,BEKSAÇ MERAL
Multiple Myelom Hastalarında Otolog Periferik Kök Hücre Nakli Esnasında Gelişen Nötropenik Ateş - USLU ATİLLA,CENGİZ SEVAL GÜLDANE,ÖZTÜRK C,,NARLI ÖZDEMİR ZEHRA,KIRCALİ EKİN,KOYUN DERYA,TOPÇUOĞLU PERVİN,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,İLHAN OSMAN,BEKSAÇ MERAL,ÖZCAN MUHİT,ARSLAN ÖNDER,GÜRMAN GÜNHAN,DEMİRER TANER,YÜKSEL MELTEM
İyi Riskli Aml’de İkinci Tam Remisyonda Allojeneik Hematopoietik Kök Hücre Nakli Tek Merkez Deneyimi - PEKCAN GÜLTEKİN,NARLI ÖZDEMİR ZEHRA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Miyelom Hastalarında Ohkhn Öncesi Kullanılan İlaçların Cmv Reaktivasyonu Üzerine Sağkalımı Azaltıcı Etkisi Olabilir mi? - YÜKSEL MELTEM,CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KIRCALİ EKİN,KOYUN DERYA,ÖZTÜRK CEMALETTİN,NARLI ÖZDEMİR ZEHRA,ÇINAR GÜLE,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AZAP ALPAY,AKAN HAMDİ,BEKSAÇ MERAL
Autologous Stem Cell Transplantatıon Versus Bortezomıb-Melphalan-Prednısone For Newly Dıagnosed Multıple Myeloma Patıents: Fınal Analysıs Of The Phase 3 Emn02/Ho95 Study - Pantani L,,Hajek R,,GAY F,,BEKSAÇ MERAL,Dozza L,,Johnsen HE,Petrucci MT,Mellqvist UH,Conticello C,,Driessen C,,Mancuso K,,Marzocchi G,,Dimopoulos MA,Zweegman S,,Zamagni E,,Wu KL,Gamberi B,,Crippa C,,Van der Holt B,,Offidani M,,Wester R,,Vincelli ID,Troia R,,Cornelisse P,,Boccadoro M,,Sonneveld P,,Cavo M,
Maternal ve Fetal Serum Örneklerinde HematopoietikSitokinler Olan Kök Hücre Faktör (Stem Cell Factor=SCF)ve Granülosit Düzeylerinin ve in vitro Etkinliklerinin Karşılaştırılmalı Analizi - Akın Yalım,YURDAKUL MESUTOĞLU PINAR,katlan doruk cevdi,ÖRGÜL GÖKÇEN,BEKSAÇ MEHMET SİNAN,BEKSAÇ MERAL
Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis - SEVAL GÜLDANE CENGİZ,Öztürk nergis,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma - Leleu X,,BEKSAÇ MERAL,Mateos MV,Pour L,,Weisel K,,Coriu D,,Obreja M,,Goldrick A,,Dimopoulos M,
Modulation of NK, T, B cell subpopulations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma - RAO P,,SAMUR M,,TALLURİ S,,DEREBAİL S,,POTLURİ L,,HAAS E,,Buonopane M,,Heubeck A,,Fulciniti M,,LazoKallanian S,,Hong K,,Peluso T,,Daley J,,Biyukov T,,BEKSAÇ MERAL,Dimopoulos MA,Hussain M,,Pierceall W,,Richardson PG,Anderson KC,Thakurta A,,AvetLoiseau H,,Munshi N,
Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM) - Kaiser M,,BEKSAÇ MERAL,Gulbrandsen N,,Schjesvold F,,Hajek R,,Moreau P,,Arriba F,,Mateos MV,West S,,Spencer A,,Rajkumar SV,Suryanarayan K,,Czorniak M,,Teng Z,,Labotka R,,Dimopoulos MA
Ex Vıvo Expansıon Of Human Umbılıcal Cord Blood Hematopoıetıc Stem Cells Wıth Valproıc Acıdor Nıcotınamıde Is Able To Accelerate Engraftment In A Nsg Mouse Transplant Model - DİLEK Y,,AKIN HY,TURASAN E,,KARAKAYA H,,ÖZIŞIK MS,FADILOĞLU E,,TANACAN A,,YURDAKUL MESUTOĞLU PINAR,BEKSAÇ MERAL
Effıcacy And Safety Of Daratumumab, Bortezomıb, And Dexamethasone (D-Vd) In Relapsed Or Refractory Multıple Myeloma (Rrmm): Updated Subgroup Analysıs Of Castor Based On Cytogenetıc Rısk - Weisel K,,Spencer A,,Lentzsch S,,AvetLoiseau H,,Mark TM,Spicka I,,Masszi T,,Lauri B,,Levin MD,Bosi A,,Hungria V,,Cavo M,,Lee JJ,Nooka A,,Quach H,,Munder M,,Lee C,,Barreto W,,Corradini P,,Min CK,ChananKhan AA,Horvath N,,Capra M,,BEKSAÇ MERAL,Ovilla R,,Jo JC,Shin HJ,Sonneveld P,,Soong D,,Casneuf T,,Chiu C,,Amin H,,Ukropec J,,Mateos MMV
Sıgnıfıcant Pom Effect On The Immune-Cellprofıles In B, T And Nk Subsets In A Large Cohortclınıcal Trıal In Relapsed/Refractory Myeloma - Prabhala R,,Samur M,,Talluri S,,Stekla M,,Acharya S,,Yenumula C,,Nanjappa P,,Lopez M,,Buonopane M,,Heubeck A,,Fulciniti M,,Szalat R,,LazoKallanian S,,Hong K,,Peluso T,,Daley J,,Biyukov T,,Oriol Rocafiguera A,,BEKSAÇ MERAL,Dimopoulos M,,Hussain M,,Pierceall W,,Richardson P,,Anderson K,,Thakurta A,,AvetLoiseau H,,Munshi N,
1st INTERNATIONAL HEALTH SCIENCE and LIFE CONGRESS (IHSLC 2018) - AKÇORA YILDIZ DİLARA,ÖZKAN TÜLİN,BEKSAÇ MERAL,SUNGUROĞLU ASUMAN
Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma - Hulin C,,Richardson PG,Attal M,,Goodman HJ,Doronin V,,Spicka I,,LeGuennec S,,Campana F,,van de Velde H,,BEKSAÇ MERAL
Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017 - Hayden PJ,Eikema DJ,Koster L,,Goldschmidt H,,Blaise D,,Potter M,,Touzeau C,,Huynh A,,Byrne J,,Hulin C,,Rabin NK,Benjamin R,,Cornelissen JJ,Nahi H,,Cook G,,Gribben JG,Meijer E,,Remnyi P,,Mayer J,,Tsirigotis P,,Bernardeschi P,,BEKSAÇ MERAL,Schönland SO,YakoubAgha I,
Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE) - Yeh Su PENG,Alsharif FAHAD,BEKSAÇ MERAL,Chen Wenming,Fantl Dorotea,Mitina TATİANA,Verburgh ESTELLE,Chng Wee Joo,Wu KwangWei,Zhang Zijing,Wan HUİ,Kim Kihyun
ANTI-PD-1 Treatment in a Family with Constitutional Mismatch Repair Deficiency Syndrome with Multiple Cancers from Turkey. Is Cancer Immunoprevention with Checkpoint Inhibitors HAS a Role in CASES with Homozygous Mutationis - ÜNAL EMEL,ÖZYÖRÜK DERYA,TAÇYILDIZ NURDAN,PINARLI FERDA,ERDOĞAN A,,Hanalioglu S,,ERDEM ARZU,BEKSAÇ MERAL
Clonal Plasma Cell Detectıon By Hıgh Sensıtıve Flow Cytometry In Aphaeresıs Product Is Poor Prognostıc And Not Increased By Use Of Plerıxafor Alone - CENGİZ SEVAL GÜLDANE,USLU A,,DALVA KLARA,BAKANAY SM,MERTER MUSTAFA,ŞAHİN UĞUR,İLHAN OSMAN,BEKSAÇ MERAL
Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,USLU A,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT - YÜKSEL MELTEM,CENGİZ SEVAL GÜLDANE,KİRCİLİ E,,D, KOYUN,ÖZTÜRK C,,NARLI ÖZDEMİR ZEHRA,ÇINAR G,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AZAP A,,AKAN HAMDİ,BEKSAÇ MERAL
Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT - YÜKSEL MELTEM,CENGİZ SEVAL GÜLDANE,KİRCİLİ E,,D, KOYUN,ÖZTÜRK C,,NARLI ÖZDEMİR ZEHRA,ÇINAR G,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AZAP A,,AKAN HAMDİ,BEKSAÇ MERAL
Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies - ARSLAN ÖNDER,ELÇİN AYŞE ESER,ATİLLA ERDEN,Şeker Şükran,Baydın Pınar,Gündüz Mehmet,ÖZEN MEHMET,Bayraktar Ulaş,İLHAN OSMAN,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: updated subgroup analysis of CASTOR - Weisel K,,Spencer A,,Lentzsch S,,AvetLoiseau H,,Mark TM,Spicka I,,Bosi A,,Hungria VTM,Cavo M,,Lee JJ,Nooka AK,Quach H,,Munder M,,BEKSAÇ MERAL,Sonneveld P,,Soong D,,Ukropec J,,Qi M,,Mateos MV
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) - Richardson PG,Attal M,,Rajkumar SV,San Miguel J,,BEKSAÇ MERAL,Spicka I,,Leleu X,,Schjesvold F,,Moreau P,,Dimopoulos MA,Huang JSY,Minarik J,,Cavo M,,Prince HM,Mace S,,Corzo KP,Campana F,,LeGuennec S,,Dubin F,,Anderson KC
Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients? - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients? - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients? - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients? - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Maintenance Therapy with the Oral Proteasome Inhibitor Ixazomib Significantly Prolongs Progression-Free Survival Post-Autologous Stem Cell Transplantation Vs Placebo in Patients with Newly Diagnosed Multiple Myeloma: Phase 3 TOURMALINE-MM3 Trial - Kaiser M,,Dimopoulos MA,Gay F,,Schjesvold FH,BEKSAÇ MERAL,Hajek R,,Weisel KC,Goldschmidt H,,Maisnar V,,Moreau P,,Min CK,Pluta A,,Chng WJ,Zweegman S,,Mateos MV,Spencer A,,Iida S,,Morgan GJ,Suryanarayan K,,Teng Z,,Skacel T,,Palumbo A,,Dash AB,Gupta N,,Labotka R,,Rajkumar SV
The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence - DALVA KLARA,CENGİZ SEVAL GÜLDANE,OZ dilek,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,Alnıaçık EZGİ,ALTAN HİLAL,ALNIAÇIK RIDVAN,SERTEL SUAT,BEKSAÇ MERAL,GÜRMAN GÜNHAN
The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence - DALVA KLARA,CENGİZ SEVAL GÜLDANE,OZ dilek,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,Alnıaçık EZGİ,ALTAN HİLAL,ALNIAÇIK RIDVAN,SERTEL SUAT,BEKSAÇ MERAL,GÜRMAN GÜNHAN
İmmun Trombositopeni (İTP) hastalarında ABO kan gruplarının birinci basamak tedavi yanıtına etkisi - AKKUŞ ERMAN,FİDAN ÇİĞDEM,KUŞTAŞ ALİ AYTUĞ,NARLI ÖZDEMİR ZEHRA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN,YÜKSEL MELTEM
Clinical experiences from around the world - BEKSAÇ MERAL
A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF DARATUMUMABMONOTHERAPY FOR PATIENTS (PTS) WITH INTERMEDIATE OR HIGH-RISK SMOLDERINGMULTIPLE MYELOMA (SMM): CENTAURUS - CAVO M,,Hofmeister CC,Chari A,,Cohen YC,Spencer A,,Voorhees P,,Estell J,,Venner C,,Sandhu I,,Jenner M,,C, Williams,van de Donk N,,BEKSAÇ MERAL,Kuppens S,,Bandekar R,,Neff T,,Heuck C,,Qi M,,Goldschmidt H,,Landgren CO
Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM) - Lonial S,,Chng WJ,BEKSAÇ MERAL,Hajek R,,Weisel K,,Mateos MV,Spencer A,,Iida S,,D, de Farias,Labotka R,,Skacel T,,Palumbo A,,Kumar S,,Dimopoulos M,
Consolıdatıon Followed By Maıntenance Vs Maıntenance Alone In Newly Dıagnosed, Transplant Elıgıble Multıple Myeloma: A Randomızed Phase 3 Study Of The European Myeloma Network (Emn02/Ho95 Mm Trıal) - Sonneveld P,,BEKSAÇ MERAL,vanderHolt M,,Dimopoulos MA,Carella A,,Ludwig H,,Driessen C,,Wester R,,Hajek R,,Cornelisse P,,Troia R,,Dozza L,,Gay F,,Cafro A,,De Rosa L,,Fiontoni G,,Mellqvis UH,Johnsen HE,Zweegman S,,Wu KL,Parreira J,,Schjesvold FH,DRozario J,,Palumbo AP,Boccadoro M,,Cavo M,
Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE) - Cavo M,,Lida S,,Blade J,,Mateos MV,Lee JJ,Garg M,,Hungria V,,BEKSAÇ MERAL,Spicka I,,Knop S,,Pour L,,Campbell P,,Jakubowiak AK,Wang J,,Wroblewski S,,Kobos R,,Qi M,,Miguel JS
Addressıng Unmet Medıcal Needs In Maıntenance Treatment For Newly Dıagnosed Multıple Myeloma (NDMM): Current Treatment Landscape And Emergıng Therapeutıc Optıons - Chng WJ,BEKSAÇ MERAL,Hajek R,,Weisel K,,Mateos MV,Spencer A,,Lida S,,Farias D,,Labotka D,,Skacel T,,Palumbo A,,Lonial S,,Kumar S,,Dimopoulos MA
State of the art myeloma treatment in Turkey and southeastern European countries on the Balkan peninsula - BEKSAÇ MERAL
IMiDs and proteasome inhibitors - BEKSAÇ MERAL
Newly Diagnosed Patients With Multiple Myeloma Multiple - BEKSAÇ MERAL
Optimal strategy for RRMM treatment - BEKSAÇ MERAL
Ölçülebilir kalıntı hastalık ve klinik önemi - BEKSAÇ MERAL
Optımısmm: Phase 3 Study Of Pomalıdomıde, Bortezomıb, And Low Dose Of Dexamentasone Vs. Bortezomıb And Low Dose Of Dexamethasone In Patıents Exposed To Lenalıdomıde After Fırst Collectıon Of Multıple Myeloma - Oriol A,,Richardson P,,BEKSAÇ MERAL,Liberati AM,Galli M,,Schjesvold F,,Lindsay J,,Weisel K,,White D,,Facon T,,Sunami K,,OGorman P,,Sonneveld P,,Robak P,,Semochkin S,,Schey S,,Yu X,,Doerr T,,Bensmaine A,,Biyukov T,,Caia A,,Zaki M,,Anderson K,,Dimopoulos M,,Miguel JS
Ölçülebilir kalıntı hastalık ve klinik önemi - BEKSAÇ MERAL
Ölçülebilir kalıntı hastalık ve klinik önemi - BEKSAÇ MERAL
State of the art myeloma treatment in Turkey and southeastern European countries on the Balkan peninsula - BEKSAÇ MERAL
State of the art myeloma treatment in Turkey and southeastern European countries on the Balkan peninsula - BEKSAÇ MERAL
Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial - Richardson PG,Rocafiguera AO,BEKSAÇ MERAL,Liberati AM,Galli M,,Schjesvold F,,Lindsay J,,Weisel K,,White D,,Facon T,,Miguel JS,Sunami K,,OGorman P,,Sonneveld P,,Yu X,Doerr T,,Bensmaine A,,Zaki MH,Anderson KC,MA Dimopoulos
Daratumumab Plus Bortezomıb-Melphalan-Prednısone (Vmp) In Elderly (≥75 Years Of Age)Patıents Wıth Newly Dıagnosed Multıple Myeloma Inelıgıble For Transplantatıon (Alcyone) - Miguel JS,Iida S,,Blade J,,Mateos MV,Lee JJ,Garg M,,Hungria V,,BEKSAÇ MERAL,Spicka I,,Knop S,,Pour L,,Campbell P,,Jakubowiak A,,Bauer MK,Wang J,,Wroblewski S,,Kobos R,,Qi M,,Cavo M,
OPTIMISMM: PHASE 3 STUDY OF POMALIDOMIDE, BORTEZOMIB, AND LOW DOSE OF DEXAMENTASONE VS. BORTEZOMIB AND LOW DOSE OF DEXAMETHASONE IN PATIENTS EXPOSED TO LENALIDOMIDE AFTER FIRST COLLECTION OF MULTIPLE MYELOMA - Richardson P,,Rocafiguera AO,BEKSAÇ MERAL,Liberati M,,Galli M,,Schjesvold F,,Lindsay J,,Weisel K,,White D,,Facon T,,Miguel JS,Sunami K,,OGorman P,,Sonneveld P,,Robak P,,Semochkin S,,Schey S,,Yu X,,Doerr T,,Bensmaine A,,Biyukov T,,Peluso T,,Zaki M,,Anderson K,,Dimopoulos M,
Fit Elderly Patients with aggressive lymphoma do not needdose reduction of conditioning regimen - İLHAN OSMAN,SEVAL GÜLDANE CENGİZ,USLU ATİLLA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience - GÜRMAN GÜNHAN,SEVAL GÜLDANE CENGİZ,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,BEKSAÇ MERAL,AKAN HAMDİ
Impact of Hepatitis B Core Antibody Seopositivity on theLiver Function Tests after Autologous Hematopoietic StemCell Transplantation For Multiple Myeloma - SEVAL GÜLDANE CENGİZ,SERTESEN ELİF,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
Kır2ds4’ün Miyelom Plazma Hücrelerine Karşı Otolog Veya Kordon Kanı Doğal Öldürücü Hücre Aracılıklı Toksisitede Rolü - YURDAKUL MESUTOĞLU PINAR,AKIN HY,,BUNSUZ MS,TURASAN E,,MERTER MUSTAFA,ÖZTÜRK C,,DALVA KLARA,BEKSAÇ MERAL
Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM) - Landgren O,,Cavo M,,Chari A,,Cohen YC,Spencer A,,Voorhees PM,,Estell J,,Sandhu I,,Jenner M,,Williams C,,van de Donk NWCJ,BEKSAÇ MERAL,Goldschmidt H,,Moreau P,,Kuppens S,,Bandekar R,,Neff T,,A, Cortoos,Clemens PL,Qi M,,Adams H,,Hofmeister CC,
Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial - Bruinink DH,van Duin M,,BEKSAÇ MERAL,Driessen C,,Ludwig H,,Vermeulen M,,Kuiper R,,Vliet MH,van der Holt B,,Hajek R,,Johnsen HE,Dimopoulos MA,Palumbo A,,Cavo M,,Sonneveld P,
A Cross Sectional Epidemiological and Survival Analysis of All Patients with Plasma Cell Disorders Recorded between 2011- 2017 in the Social Insurance System of Turkey - Dag M,,BEKSAÇ MERAL
Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients - ATİLLA ERDEN,TOPÇUOĞLU PERVİN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,DEMİRER TANER,ÖZCAN MUHİT,BEKSAÇ MERAL,İLHAN OSMAN,AKAN HAMDİ,ARSLAN ÖNDER,GÜRMAN GÜNHAN,TOPRAK SELAMİ KOÇAK
Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM) - Chng WJ,BEKSAÇ MERAL,Hajek R,,Weisel K,,Mateos MV,Spencer A,,Lida S,,Farias D,,Labotka R,,Skacel T,,Palumbo A,,Lonial S,,S, Kumar,Dimopoulos MA
Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). - Lonial S,,Dimopoulos MA,Weisel K,,White D,,Moreau P,,Mateos MV,Miguel JS,Anderson KC,Shpilberg O,,Grosicki S,,Spicka I,,Croneck AW,Magen H,,Belch A,,Reece DE,BEKSAÇ MERAL,Shelat S,,Sy O,,Singhal AK,Richardson PG
Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience - Cengiz Seval G,,BULAT B,,Ozel F,,Tasci O,,Kuzu I,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,ARSLAN ÖNDER
Patıent Reported Outcomes (Pros) Of Multıple Myeloma (Mm) Patıents From The Panorama-1 Study Who Have Receıved At Least Two Prıor Regımens Includıng Bortezomıb And An Immunomodulatory Agent - Richardson PG,Hungria V,,Yoon SS,BEKSAÇ MERAL,Dimopoulos MA,Elghandour A,,Jedrzejczak WW,Nakorn TN,Siritanaratkul N,,Schlossman R,,Hou J,,Moreau P,,Lonial S,,Lee JH,Einsele H,,Binlich F,,Sopala M,,Roy A,,Panneerselvam A,,Miguel JS
Real World Retrospectıve Analysıs Of Extramedullary Dısease From Balkan Myeloma Study Group And Barcelona Unıversıty: Clınıcal Features And Outcome - BEKSAÇ MERAL,Kanellias N,,Rosinol L,,CENGİZ GS,Ozet G,,Goranova V,,Coriu D,,Bila J,,Ozsan H,,Balic LI,Ivanaj A,,Kastritis E,,Blade J,,Dimopoulos MA
Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM) - Weisel K,,Dimopoulos MA,Lonial S,,White D,,Moreau P,,Mateos MV,Miguel JS,Anderson K,,Shpilberg O,,Grosicki S,,Spicka I,,Croneck AW,Magen H,,Belch A,,Reece D,,BEKSAÇ MERAL,Shelat SG,Mekan S,,O, Sy,Singhal AK,Richardson PG
Impact Of Mesenchymal Stromal Cells On In Vıtro Growth Of Fresh Human Myeloma Plasma Cells And On Autologous/Cord Blood Nk Cell Medıated Cytotoxıcıty - YURDAKUL MESUTOĞLU PINAR,AKIN HY,AYDIN G,,SENGUN MB,TURASAN E,,DALVA KLARA,BEKSAÇ MERAL
Impact Of Mesenchymal Stromal Cells On In Vıtro Growth Of Fresh Human Myeloma Plasma Cells And On Autologous/Cord Blood Nk Cell Medıated Cytotoxıcıty - YURDAKUL MESUTOĞLU PINAR,AKIN HY,AYDIN G,,SENGUN MB,TURASAN E,,DALVA KLARA,BEKSAÇ MERAL
Real-World Data in Relapsed Refractory Myeloma Patients Treated with Pomalidomide, a Multicenter Turkish Experience - ÖZSAN GÜNER HAYRİ,SEVİNDİK ÖMÜR GÖKMEN,SEVİL SADRİ,HACIOĞLU SİBEL KABUKCU,KAYA SÜREYYA YİĞİT,GEDUK AYFER,URAL ALİ UĞUR,TUĞLULAR TÜLİN FIRAT,ÖZKOCAMAN VİLDAN,DEMİR AHMET MUZAFFER,AYDIN YILDIZ,ÇAĞLAYAN GÜLSÜM AKGÜN,AYDOĞDU İSMET,PEHLİVAN MUSTAFA,YARADILMIŞ İBRAHİM MUAZ,KARAKUŞ VOLKAN,YILMAZ MEHMET,BEKSAÇ MERAL
Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma - ATİLLA ERDEN,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,AKAN HAMDİ,ARSLAN ÖNDER,DEMİRER TANER,BEKSAÇ MERAL,İLHAN OSMAN,ÖZCAN MUHİT,GÜRMAN GÜNHAN
Phase 3 ELOQUENT-2 study: extended 4-y follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM) - Lonial Sagar,Singhal Anil,Moreau Philippe,Shpilberg Ofer,Reece Donna,Mateos Maria,Grosicki Sebastian,Belch Andrew,White Darrell,Sy Oumar,San Miguel Jesus,Magen nativ Hila,Walter Croneck Adam,BEKSAÇ MERAL,Dimopoulos Meletios,Spicka Ivan,Weisel Katja,Richardson Paul,Anderson Kenneth,Mekan Sabeen
Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study - Hofmeister CC,Chari A,Cohen Y,Voorhee PM,Estel J,Venner CP,Sandhu I,Jenner MW,Williams C,Cavo M,Donk NV,BEKSAÇ MERAL,Kuppens S,Bandekar R,Neff T,Heuck C,Qi M,Goldschmidt H,Landgren O
Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study - Cavo M,Hjek R,Pantani L,BEKSAÇ MERAL,Oliva S,Dozza L,Johnsen HE,Petrucci MT,Mellqvist UH,Conticello C,Driessen C,Marzocchi G,Dimopoulos MA,Zweegman S,Wu KL,Gamberi B,Crippa C,Holt BV,Offidani M,Wester R,Vincelli ID,Troia R,Cornelisse P,Boccadoro M,Sonneveld P
REAL WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH POMALIDOMIDE, A MULTICENTER TURKISH EXPERİENCE - ÖZSAN GÜNER HAYRİ,SEVİNDİK ÖMÜR GÖKMEN,sevil sadri,HACIOĞLU SİBEL,KAYA SÜREYYA,GEDUK AYFER,URAL ALİ UĞUR,TUĞLULAR AYŞE TÜLİN,ÖZKOCAMAN VİLDAN,DEMİR AHMET MUZAFFER,AYDIN YILDIZ,AKGÜN ÇAĞLIYAN GÜLSÜM,AYDOĞDU İSMET,PEHLİVAN MUSTAFA,YARADILMIŞ İBRAHİM MUAZ,KARAKUŞ VOLKAN,YILMAZ MEHMET,BEKSAÇ MERAL
Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma - İLHAN OSMAN,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA - Dimopoulos MA,Lonial S,White D,Moreau P,Mateos MV,San Miguel J,Anderson KC,Shpilberg O,Grosicki S,Spicka I,A WalterCroneck,Magen H,Belch A,Reece DE,BEKSAÇ MERAL,Mekan S,Sy O,Singhal AK,Richardson PG,Weisel K
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: SINGLE CENTER EXPERIENCE - TOPRAK SELAMİ KOÇAK,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,DEMİRER TANER,ÖZCAN MUHİT,ARAT MUTLU,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,konuk nahide,uysal akın,GÜRMAN GÜNHAN
Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia. - GÜRMAN GÜNHAN,gülöksüz gözde aydemir,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,ARSLAN ÖNDER,DEMİRER TANER,İLHAN OSMAN,BEKSAÇ MERAL
A single center experience with two decades of follow-up on patients with hairy cell leukemia. - İLHAN OSMAN,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,DEMİRER TANER,ARSLAN ÖNDER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
